Prehabilitation With Resistance-exercise Training for Breast Cancer Neoadjuvant Therapy

Breast cancer stands as the foremost cause of cancer-related deaths among women worldwide, with the highest incidence of any cancer type. The choice of therapeutic interventions hinges upon factors like cancer stage, cell subtype, and tumor size. Consequently, individuals with more aggressive tumors, such as HER+2 and Triple Negative, or larger tumors often undergo neoadjuvant chemotherapy before breast surgery. However, these anticancer treatments come with side effects like cancer-related fatigue, reduced functional capacity, and changes in body composition, notably skeletal muscle atrophy.

Trial Details

NCT ID
NCT06309290
Phase
NA
Sponsor
Universidad de La Frontera
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • Prehabilitation with resistance-exercise training
  • Usual care program
Locations (sample)
  • Santiago, Chile|-33.45694,-70.64827
  • Temuco, Chile|-38.73628,-72.59738

Key Eligibility Criteria

  • Postmenopausal women with breast cancer in stages I, II and III with luminal breast tumor, HER2+ or TNBC
  • Indication for neoadjuvant chemotherapy
  • Candidates for curative breast surgery
  • Body mass index: 18.5 \<BMI \<30 kg/m2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →